Michael J Wagner
Overview
Explore the profile of Michael J Wagner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
1921
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McKenzie Jr K, Banek N, Wagner M
Materials (Basel)
. 2025 Mar;
18(5).
PMID: 40077251
The conversion of biochar, the low value byproduct of pyrolysis bio-oil production from biomass multi-walled carbon nanotubes (MWCNTs) and carbon nanochains (CNCs), is reported. It is shown that biomass can...
2.
Womble M, McKenzie Jr K, Wagner M
Sci Rep
. 2025 Feb;
15(1):5868.
PMID: 39966523
The theoretical energy density of Li-O batteries is more than an order of magnitude larger than the current generation of Li-ion batteries. However, their practical performance is far less, in...
3.
Kong L, Yan G, Hu K, Yu Y, Conte N, McKenzie Jr K, et al.
Nat Commun
. 2025 Jan;
16(1):806.
PMID: 39827233
As Li-ion batteries are increasingly being deployed in electric vehicles and grid-level energy storage, the demand for Li is growing rapidly. Extracting lithium from alternative aqueous sources such as geothermal...
4.
Livingston J, Blay J, Trent J, Valverde C, Agulnik M, Gounder M, et al.
Clin Cancer Res
. 2024 Dec;
31(4):628-638.
PMID: 39660994
Purpose: FHD-609, a potent, selective, heterobifunctional degrader of bromodomain-containing protein 9 (BRD9), was evaluated for treating patients with advanced synovial sarcoma or SMARCB1-deficient tumors. Patients And Methods: In this multinational,...
5.
Lurain K, Ramaswami R, Ekwede I, Eulo V, Goyal G, Menon M, et al.
J Clin Oncol
. 2024 Oct;
43(4):432-442.
PMID: 39356983
Purpose: Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort. Methods: In...
6.
Gundle K, Rajasekaran K, Houlton J, Deutsch G, Ow T, Maki R, et al.
Front Pharmacol
. 2024 Apr;
15:1367581.
PMID: 38681192
Drug development is systemically inefficient. Research and development costs for novel therapeutics average hundreds of millions to billions of dollars, with the overall likelihood of approval estimated to be as...
7.
Anidi I, Sakai S, Brooks K, Fling S, Wagner M, Lurain K, et al.
Open Forum Infect Dis
. 2024 Apr;
11(5):ofae183.
PMID: 38680611
Blockade of the co-inhibitory receptor PD-1 enhances antitumor responses by boosting the function of antigen-specific T cells. Although rare, PD-1 blockade in patients with cancer can lead to exacerbation of...
8.
Lim J, Chen E, Schaub S, Wagner M
Mol Genet Genomic Med
. 2024 Apr;
12(4):e2423.
PMID: 38622850
Background: Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal soft tissue sarcomas that often present diagnostic challenges due to their wide and varied morphology. A subset of IMTs have fusions involving...
9.
Wagner M, Ravi V, Schaub S, Kim E, Sharib J, Mogal H, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e246235.
PMID: 38607625
Importance: Angiosarcoma is an aggressive vascular malignant neoplasm presenting either as a primary or secondary cancer, often arising after radiotherapy or in the context of preexisting lymphedema. Comprehensive data describing...
10.
Briercheck E, Wrigglesworth J, Garcia-Gonzalez I, Scheepers C, Ong M, Venkatesh V, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e244898.
PMID: 38568688
Importance: Gastrointestinal stromal tumor (GIST) is a rare cancer treated with the tyrosine kinase inhibitors imatinib mesylate or sunitinib malate. In general, in low- and middle-income countries (LMICs), access to...